Related Experiment Video
Updated: Aug 7, 2025
10:17
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
9.7K
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava1, Stephen M Stahl2,3, Sara De Martin4
1Department of Psychiatry, Massachusetts General Hospital, Boston, MA, 02114, USA.
Summary
Esmethadone, a novel N-methyl-D-aspartate receptor (NMDAR) antagonist, shows promise for treating major depressive disorder (MDD) and other neurological conditions. Research explores its potential and compares it with existing NMDAR antagonists.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Development
Background:
- Major depressive disorder (MDD) and other neurological conditions remain significant health challenges.
- N-methyl-D-aspartate receptor (NMDAR) antagonists represent a novel therapeutic class with demonstrated efficacy.
- Understanding the role of NMDARs in neural plasticity is crucial for developing effective treatments.
Purpose of the Study:
- To review recent studies on esmethadone as a potential new drug.
- To compare esmethadone with other uncompetitive NMDAR antagonists, including esketamine, ketamine, dextromethorphan, and memantine.
- To advance the understanding of NMDARs in neural plasticity and their role in neuropsychiatric disorders.
Main Methods:
- In silico, in vitro, in vivo, and clinical data analysis.
- Comparative review of NMDAR antagonists.
- Literature review of recent studies on esmethadone.
Main Results:
- Esmethadone is a promising uncompetitive NMDAR antagonist.
- NMDAR antagonists show efficacy in treating major depressive disorder (MDD), Alzheimer's dementia, and pseudobulbar affect.
- Data suggests NMDAR antagonists may offer rapid antidepressant effects.
Conclusions:
- Esmethadone holds potential as a novel therapeutic agent.
- Further research into NMDAR antagonists can illuminate the neurobiology of MDD and other neuropsychiatric disorders.
- Understanding NMDARs in neural plasticity is key for future therapeutic strategies.
Keywords:
EsketamineEsmethadoneKetamineMajor depressive disorderN-Methyl-D-aspartate receptorREL-1017More Related Videos
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
289
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
289
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
486
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
486
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
213
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
213
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
363
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
363
01:25Antidepressant Drugs: Overview
656
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
656
01:28Drug Therapy
82
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
82